Plain-English translation of NCT07467447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing a medication called retatrutide as a treatment for obesity and overweight. Participants will receive weekly injections of the medication at different doses, or placebo (a dummy injection), for 48 weeks to see if the treatment helps with weight loss. The study will track how much weight people lose and monitor how safe the medication is.
Current weight management options don't work well enough for everyone, and researchers are looking for new treatments that can help people lose weight more effectively. This trial is testing whether this medication could be a helpful new option for people struggling with their weight.
You likely qualify if…
You likely don't qualify if…
You will start with a screening visit (up to 6 weeks) to confirm you qualify. Then you'll be randomly assigned to receive either the medication or placebo as a weekly injection. Some participants will start at a lower dose that gradually increases to the target dose, while others may start at the target dose right away. You'll visit the clinic regularly over 48 weeks to get your injection, have your weight measured, answer health questions, and get blood tests. After 48 weeks, you'll have 4 more weeks of follow-up visits to make sure everything is safe.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
China